US 8729094

Patent Overview — US8729094B2

Title: Liquid pharmaceutical formulations of palonosetron

Patent number: US8729094B2 (application US13/902,132; also published as US20130261150A1)

Assignee/owner (per source): Current assignee listed as HAS Helsinn Advanced Synthesis SA; Helsinn Birex Pharmaceuticals Ltd; Helsinn Therapeutics US Inc. Original assignee listed as Helsinn Healthcare SA and Roche Palo Alto LLC.

Key dates (per source): Priority date 2003-01-30 (priority claimed from PCT/EP2004/000888, filed 2004-01-30); filing date 2013-05-24; publication date 2014-05-20; anticipated expiration 2024-01-30; legal status "Expired - Lifetime."

Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Alberto Macciocchi, Andrew Miksztal, Thomas Malefyt, Kathleen M Lee.

Purpose and plain-language scope: The patent concerns liquid pharmaceutical formulations of palonosetron, a compound whose chemical structure is given as the hydrochloride salt (CPZBLNMUGSZIPR-NVXWUHKLSA-N). The classification listed is A61K (preparations for medical, dental or toiletry purposes), consistent with a medicinal formulation. The "prior art keywords" fields in the source indicate the subject matter relates to a solution, human use, palonosetron, intravenous administration, and mannitol. In plain terms, the excerpt indicates a liquid (solution) formulation of palonosetron suitable for intravenous administration to humans, with mannitol appearing among the formulation components discussed.

Source: https://patents.google.com/patent/[US8729094](/patent/US8729094)/en

What the excerpt does not establish: The supplied text is largely bibliographic and does not include the claims, written description, examples, or figures. Therefore the exact scope of the claims, specific concentrations, excipient amounts, pH, dosage regimens, and any stated advantages or data are not established here. It also does not establish the full list of cited prior art or the basis for patentability. Statements about assignees, dates, and legal status are as listed by the source, which notes legal status is an assumption and not a legal conclusion; no independent verification is asserted. Litigation, ownership transfers, validity, and prior-art analysis are outside this overview by instruction and are not evaluated.

I'll research litigation involving US 8,729,094 using the litigation sources you specified.

I have strong initial results. Let me dig deeper into the specific case dockets and PTAB proceedings.

Let me get the full case list from Docket Alarm and check specific case outcomes.

Litigation involving US 8,729,094 ("Liquid pharmaceutical formulations of palonosetron")

Bottom line: US 8,729,094 (the "'094 patent") has been asserted in Hatch-Waxman litigation brought by Helsinn Healthcare S.A. and Roche Palo Alto LLC against generic palonosetron (Aloxi®) ANDA/505(b)(2) filers in the District of New Jersey and the District of Delaware, and was the subject of four inter partes review petitions at the PTAB in 2015. It was also an Orange Book-listed patent for NDA No. 021372 (Aloxi®), expiring January 30, 2024 (July 30, 2024 with pediatric exclusivity), use code U‑528.

All identifiers below are reproduced as they appear in the sources; I have not corrected any numbers.

1. District court cases where the '094 patent was specifically asserted

Note on the Teva '094 case number: the injunction and claim-construction opinions in the '094 matter appear under D.N.J. No. 2:14-cv-04274, while a related Teva palonosetron action appears as No. 3:14-cv-06341. Both are New Jersey dockets involving the same patent family; I flag this because the docket family is large and I could not independently reconcile every docket entry.

2. PTAB (inter partes review) proceedings on the '094 patent

Four IPR petitions were filed on July 3, 2015 by [Dr. Reddy's Laboratories, Ltd.](/litigations/by-plaintiff/Dr.%20Reddy's%20Laboratories%2C%20Ltd.) et al. against Helsinn Healthcare S.A. et al., challenging claims 22–27 and 30 of US 8,729,094 (application 13/902,132, Tech Center 1600):

The '094 patent's own Google Patents page lists these four proceedings as "filed (Settlement)," consistent with the joint motions to terminate filed 2015-10-09 and the Board's termination 2015-10-14.

3. Appellate / Supreme Court history

Important caveat: the well-known appellate decision Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017) (rev'g D.N.J.; on-sale bar invalidity), and the subsequent Supreme Court decision in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., No. 17-1229 (cert. granted June 25, 2018; 2018-2019 term), concerned the '724, '725, '424, and '219 patents — not the '094 patent. Cases 16-1284 (Fed. Cir.) and the district court opinions of Nov. 13, 2015 / Mar. 3, 2016 in D.N.J. No. 11-3962 likewise involved the '724/'725/'424/'219 patents. I found no appeal specifically addressing the '094 patent's claims. I state this explicitly so the '094 patent is not conflated with the different patents that reached the Federal Circuit and Supreme Court.

4. Other palonosetron litigation in the same family (not individually confirmed to assert the '094 patent)

The '094 patent's Google Patents page lists a large set of family-level litigations. Because the '094 patent issued on 2014-05-20 (well after the 2011–2013 suits), not every docket below necessarily asserted the '094 patent. Dockets listed include:

• D.N.J.: 2:14-cv-04274; 3:14-cv-04274; 3:14-cv-06341; 3:15-cv-01228; 3:15-cv-02078; 2:15-cv-02077; 3:15-cv-02077; 3:15-cv-07015; 3:15-cv-08132; 3:16-cv-00173; 2:16-cv-00173; 3:16-cv-04239; 2:16-cv-04239; 2:17-cv-03216; 3:17-cv-03216
• D. Del.: 1:13-cv-02101; 1:14-cv-00709; 1:15-cv-00264; 1:15-cv-00265; 1:15-cv-00865; 1:18-cv-01674
• E.D. Pa.: 2:15-cv-06392

Docket Alarm's search for patent 8,729,094 also returns:

• Helsinn Healthcare S.A. v. Zydus Pharmaceuticals (USA) Inc. et al, D.N.J. No. 3:16-cv-04239 (filed 2016-07-13; Judge Stanley R. Chesler / Mag. Cathy L. Waldor)
• Helsinn Healthcare S.A. et al v. Sagent Pharmaceuticals, Inc., D.N.J. No. 3:16-cv-00681
• Helsinn Healthcare S.A. et al v. Fresenius Kabi USA, LLC et al, D.N.J. No. 3:15-cv-07378 (filed 2015-10-08)
• Helsinn Healthcare S.A. et al v. Par Pharmaceutical Companies, Inc. et al, D.N.J. No. 3:15-cv-02078 (filed 2015-03-23)
• Helsinn Healthcare S.A. v. Hospira Inc., D. Del. No. 1:15-cv-00264 (filed 2015-03-25)
• An additional 2015-09-23 D.N.J. docket (3:15-cv-07015)
• Helsinn Healthcare, S.A. et al v. Teva Pharmaceuticals USA, Inc. et al, D.N.J. No. 3:14-cv-06341 (filed 2014-10-13)

Separately, the 2011–2013 first-filer actions — D.N.J. consolidated Nos. 11-03962 and 11-05579 against Dr. Reddy's, Sandoz, and Teva (asserting the '724, '725, '424, and '219 patents) — resulted in settlements: Sandoz (Jan. 2015) and Dr. Reddy's (Oct. 13, 2015) were permitted to launch generic Aloxi® on September 30, 2018 "or earlier under certain circumstances." Sagent's brief represents that Helsinn "fil[ed] infringement actions against at least fifteen other ANDA sponsors in addition to Teva, Dr. Reddy's, Sandoz, and Sagent," and identifies Aurobindo Pharma Ltd.; Akorn, Inc.; Qilu Pharmaceutical Co.; Somerset Therapeutics, LLC; and Fresenius Kabi USA, LLC as other settled ANDA sponsors. Those fifteen-plus actions are family-level; I could not individually verify which asserted the '094 patent.

5. Confidence and limitations

• High confidence: the four IPR proceedings (IPR2015-01550/-01551/-01553/-01554) targeted the '094 patent, were filed 2015-07-03 by Dr. Reddy's, and were terminated ~2015-10-14 by settlement; Sagent and Hospira are documented as asserting the '094 patent; the '094 preliminary-injunction denial in D.N.J. No. 2:14-cv-04274.
• Medium confidence: the precise alignment of docket numbers within the Teva NJ file (2:14-cv-04274 vs. 3:14-cv-06341) and the full inventory of '094-asserting dockets. Because '094 issued in 2014, later-filed 2015–2017 dockets are more likely to have asserted it, but I could not confirm each one from the available records.
• Unverified: final disposition/judgment on the '094 patent's own claims (as opposed to the '724/'725/'424/'219 claims invalidated in Helsinn v. Teva, 855 F.3d 1356, and addressed by the Supreme Court in No. 17-1229). The '094 patent's Google Patents status shows "Expired – Lifetime," with anticipated expiration 2024-01-30.

If you want, I can attempt to pull the PACER/CourtListener docket sheets for any specific case number above to confirm the exact '094-specific counts, settlement dates, and final judgment language.

I'll research the PTAB docket for this patent before writing anything.

Four IPRs are surfacing. Let me pin down the petition grounds, claim scope, and confirm nothing else is pending.

Let me nail down each petition's claim set and confirm nothing else was ever filed against the '094.

PTAB proceedings on US 8,729,094 — defendant-facing analysis

Source-reconciliation note (read first). The structured "PTAB proceedings on file" block in this prompt reports that the USPTO ODP API returns no AIA trial proceedings for US 8,729,094. That block is contradicted by the patent's own Google Patents record in the same corpus, which lists four PTAB cases on this exact patent (IPR2015-01550, -01551, -01553, -01554, each marked "Settlement"), and by primary PTAB documents I located on PTACTS/Docket Alarm. I treat the four IPRs below as the operative list and flag the ODP gap; nothing in either source shows any proceeding beyond these four. No proceeding number below is invented.

Proceedings overview

Four AIA trials, all Inter Partes Review, all filed 2015-07-03 by Dr. Reddy's Laboratories, and all terminated on 2015-10-14 by joint motion before any institution decision — therefore zero claims invalidated, zero claims sustained, zero final written decisions, and zero Federal Circuit appeals. The bottom line for a defendant is unusual and cuts against the usual reading of an "unadjudicated" patent: the '094 claims were never PTAB-tested, so there is no IPR kill-shot to cite — but the patent itself expired on 2024-01-30 ("Expired - Lifetime," anticipated expiration per the Google Patents record), and the Senate-style estoppel of 35 U.S.C. § 315(e)(2) never attached because no trial was instituted. In practical terms: this is not a "hardened by two IPRs" patent, and it is not a "claims 1-5 are canceled" patent. It is an expired patent whose PTAB file is a four-case settlement stub.

IPR2015-01554 — Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A. and Roche Palo Alto LLC

• Type: Inter Partes Review (35 U.S.C. §§ 311–319)
• Filed: 2015-07-03 (corrected petition filed 2015-07-21)
• Status: Terminated — settlement. The Board's order is styled "TERMINATION OF PROCEEDINGS, 37 C.F.R. § 42.72," entered 2015-10-14 (Paper 14). Note: third-party trackers (e.g., GreyB/IP Verse) label these four as "Institution Denied." That label is imprecise — the Board never reached an institution decision. The order states the cases were still in the "preliminary proceeding stage" and that the joint motions to terminate were granted. "Terminated pre-institution on settlement" is the accurate description.
• Judge panel: Lora M. Green, Christopher G. Paulraj, and Robert A. Pollock, Administrative Patent Judges; order authored by Judge Pollock. (A single order was entered in all four cases.)
• Petition grounds: § 103 obviousness of claims 22–27 and 30 of the '094 patent (per the corrected petition caption) over Chelly (Ex. 1012) in view of Tang (Ex. 1019), Gandara (Ex. 1027), Avis (Ex. 1050), and the 2001 Physicians' Desk Reference (Exs. 1015–1017). Petitioner's expert support: Declarations of Dr. William P. McGuire (Ex. 1021), Dr. David G. Frame (Ex. 1023), and Dr. Patrick P. DeLuca (Ex. 1040). The petition argued the claim elements — 0.05 mg/mL concentration, 5 mL unit dose, pH 5.0±0.5, mannitol, EDTA, citrate — were "mere optimizations," citing the '094 specification's own Examples 1–3 optimization language. No § 102 or § 112 grounds appear in the retrieved petition text.
• Institution decision: none. The three-month institution window had not run; Helsinn's preliminary response was due 2015-10-21 and was never filed.
• Final Written Decision: none issued — no claim was canceled or confirmed.
• Settlement / termination: Joint motions to terminate filed 2015-10-09; granted 2015-10-14. The settlement agreement was filed as Exhibit 2001 in each case and granted business-confidential treatment under 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), kept separate from the public patent file. Terms are not public. The joint motion also states the consolidated D.N.J. action Helsinn Healthcare S.A. et al. v. Dr. Reddy's Laboratories, Ltd. et al., Nos. 14-4274 and 14-6341 (D.N.J.), was settled as to Dr. Reddy's, with a request to dismiss to follow.
• Appeal: none. With no FWD there was nothing appealable; no CAFC docket exists for this IPR.
• Defensive value: The claim set DRL attacked here (claims 22–27, 30) has never been construed by the PTAB, so there is no estoppel or Board precedent to leverage. The petition itself is still useful as a free roadmap — it is a fully drafted § 103 obviousness attack on the '094 independent claim 22 family, with expert declarations, sitting in the file. Because no FWD issued, § 315(e)(2) estoppel never attached to DRL or its privies.
• Sources: Board termination order (Docket Alarm copy) — https://www.docketalarm.com/cases/PTAB/IPR2015-01551/Inter_Partes_Review_of_U.S._Pat._8729094/docs/10-14-2015-Board/Termination___Settlement-14-Termination_of_the_Proceedings.pdf ; corrected petition caption — https://www.docketalarm.com/cases/PTAB/IPR2015-01554/Inter_Partes_Review_of_U.S._Pat._8729094/docs/07-21-2015-Petitioner/Notice-6-Corrected_Petition_for_Inter_Partes_Review_of_Claims_22_27_and_30_of_US_Patent_No_8,729,094.pdf ; PTAB E2E counterparts under https://ptacts.uspto.gov/ptacts/

IPR2015-01550 — Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A. and Roche Palo Alto LLC

• Type: Inter Partes Review
• Filed: 2015-07-03 (attorney docket REDDY 7.1R-013)
• Status: Terminated — settlement (Paper 14, 2015-10-14)
• Judge panel: Green, Paulraj, Pollock (APJs), per the common termination order
• Petition grounds: § 103 obviousness, same art combination as -01554 (Chelly + Tang + Gandara + Avis + 2001 PDR), same three expert declarations. The specific claim set challenged in this petition is not confirmed in the sources I retrieved — I will not guess it. Given the four-petition structure across a 30-claim patent with independent claims 1, 5, 13 and 22, a claim-by-claim partition is the natural inference, but that is inference, not record.
• Institution decision: none — terminated in the preliminary proceeding stage before any decision
• Final Written Decision: none issued
• Settlement / termination: Joint motion to terminate filed 2015-10-09 (Paper 11), granted 2015-10-14; settlement agreement (Ex. 2001) treated as business confidential under § 317(b) / § 42.74(c). Terms confidential. Motion text: "Termination is appropriate because this inter partes review proceeding has not been instituted... Helsinn has not filed a preliminary response, which is due on October 21, 2015. Termination... is also appropriate because... the Board has not yet decided any merits of the proceeding."
• Appeal: none
• Defensive value: Same posture as -01554 — no estoppel, no adjudication, but a public, usable invalidity record. Note the Google Patents litigation block in this prompt lists all four IPRs with a blank "Petitioner" field; the petitioner of record is Dr. Reddy's, not a defensive aggregator (see Strategic summary).
• Sources: Joint Motion to Terminate — https://gaeflexstaging-dot-docketupdate.appspot.com/cases/PTAB/IPR2015-01550/Inter_Partes_Review_of_U.S._Pat._8729094/10-09-2015-Patent_Owner/Motion-11-Joint_Motion_to_Terminate/ ; PTAB E2E petition file — https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1459899](/patent/1459899)/

IPR2015-01551 — Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A. and Roche Palo Alto LLC

• Type: Inter Partes Review
• Filed: 2015-07-03 (attorney docket REDDY 7.1R-012)
• Status: Terminated — settlement (Paper 14, 2015-10-14)
• Judge panel: Green, Paulraj, Pollock (APJs)
• Petition grounds: § 103 obviousness; same art set and declarations as the companion petitions. Claim set challenged not confirmed in retrieved sources.
• Institution decision: none
• Final Written Decision: none issued
• Settlement / termination: Joint motion + joint request for business-confidential treatment filed 2015-10-09; granted 2015-10-14. Terms confidential. The joint request under § 317(b) / § 42.74(c) is signed by Thomas M. Palisi (Lerner David) for DRL and Eric W. Dittmann (Paul Hastings) for Helsinn/Roche.
• Appeal: none
• Defensive value: Identical to the others — nothing adjudicated, nothing estopped. Do not cite this proceeding as invalidating anything.
• Sources: https://www.docketalarm.com/cases/PTAB/IPR2015-01551/Inter_Partes_Review_of_U.S._Pat._8729094/ ; PTACTS — https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1462972](/patent/1462972)/

IPR2015-01553 — Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. v. Helsinn Healthcare S.A. and Roche Palo Alto LLC

• Type: Inter Partes Review
• Filed: 2015-07-03 (attorney docket REDDY 7.1R-010)
• Status: Terminated — settlement (Paper 14, 2015-10-14)
• Judge panel: Green, Paulraj, Pollock (APJs)
• Petition grounds: § 103 obviousness; same art set and declarations. Claim set challenged not confirmed in retrieved sources.
• Institution decision: none
• Final Written Decision: none issued
• Settlement / termination: Joint motion to terminate filed 2015-10-09 with the other three; granted 2015-10-14. Terms confidential.
• Appeal: none
• Defensive value: Same. One practical caveat: several third-party databases mis-code these four as "Institution Denied." If you are building a defensive narrative, do not rely on that label — pull the Board's 2015-10-14 order, which says the opposite of a merits denial.
• Sources: https://www.docketalarm.com/cases/PTAB/IPR2015-01553/Inter_Partes_Review_of_U.S._Pat._8729094/ ; PTACTS — https://ptacts.uspto.gov/ptacts/public-informations/petitions/[1463036](/patent/1463036)/

Strategic summary

Claim status of the '094 patent. Every one of claims 1–30 is untested at the PTAB. No claim was canceled, no claim was confirmed, and no FWD exists. The patent's administrative status is "Expired - Lifetime," with an anticipated expiration of 2024-01-30 (20 years from the 2004-01-30 PCT/EP2004/000004-family filing). For a party receiving a demand letter today (2026-09-30), the practical question is not claim scope but damages: under 35 U.S.C. § 286 the recovery window would be the six years preceding suit, intersected with the pre-expiration period — i.e., roughly 2020-09-30 through 2024-01-30. Note also that although the PTAB never substantively tested these claims, the '094 claims (including claims 1 and 4) were construed and litigated in the ANDA cases, and related-family patents were the subject of Federal Circuit appeals including Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017). That decision, however, came out of the district court cases (Nos. 11-3962/11-5579/13-5815 and related), not an appeal of any of these four IPRs — do not conflate them.

Estoppel landscape. Statutory estoppel requires a final written decision. Because all four petitions were terminated before institution, 35 U.S.C. § 315(e)(1) and (e)(2) never triggered: DRL and its privies are not barred from re-raising the Chelly/Tang/Gandara/Avis/PDR grounds, at the Board or in litigation. Equally, there is no IPR-driven narrowing to import into a § 112 or indefiniteness defense, and no adverse Board claim construction to work with. If a settlement agreement between Helsinn and DRL contains contractual limits on DRL's future challenges, that is not public — Exhibit 2001 was sequestered as business confidential — and cannot be relied on by a third party either way. The district court litigation around this family did produce prosecution-statement and claim-construction material that is genuinely useful to a defendant (e.g., the patentee's repeated statements to the PTO that the mannitol/EDTA stability discoveries were "only" made at pH 4.0–6.0, which underpinned a proposed narrow construction of "stable at 24 months when stored at room temperature" in the Cipla D. Del. action), but that material is litigation-sourced, not PTAB-sourced.

Pattern signals. Yes — one petitioner, four petitions, one day. DRL filed all four IPRs on 2015-07-03 and settled all four about three months later, contemporaneously with settling the consolidated D.N.J. actions (14-4274/14-6341) as to Dr. Reddy's. That is a coordinated Hatch-Waxman/settlement play, not a stand-alone PTAB campaign, and it means the '094 patent's PTAB record was never stress-tested. The same petitioner did continue attacking the family: DRL filed PGR2016-00008 against sibling US 9,173,942 (claims 1–19) after the '094 settlements — so the family-wide pattern is "settle the '094, keep pressing the later continuations." I did not verify the outcome of PGR2016-00008, and it is not a proceeding on the '094 patent; treat it as context only. No defensive aggregator was a party. The Google Patents litigation block cites Unified Patents, but only as the data provider for its litigation feed — the petitioner of record in all four IPRs is Dr. Reddy's Laboratories, Ltd./Inc. No Unified Patents IPR, no ex parte reexam, and no CBM on this patent appears in any source I checked. The patent owner (Helsinn) has no PTAB appeal history on this patent, because it never had a FWD to appeal.

Recommended next steps

1. Do not over-claim the PTAB record in correspondence. If opposing counsel asserts that the '094 patent "has survived IPR," the precise answer is that it never faced institution — the four DRL petitions were terminated on 2015-10-14 in the preliminary proceeding stage. Quote the Board: "As no trial has been instituted based on any of these petitions, all proceedings are in the preliminary proceeding stage... the joint motions to terminate the proceedings are GRANTED." Link the order: https://www.docketalarm.com/cases/PTAB/IPR2015-01551/Inter_Partes_Review_of_U.S._Pat._8729094/docs/10-14-2015-Board/Termination___Settlement-14-Termination_of_the_Proceedings.pdf
2. Lead with expiration, not PTAB. Confirm the 2024-01-30 expiry in USPTO Patent Center / PAIR (the Google Patents "anticipated expiration" field is an assumption, not a legal conclusion) and run the § 286 damages window. For most modern assertions, the expiry plus the six-year lookback is a more decisive defense than any IPR argument.
3. Re-use the DRL petitions as a free invalidity roadmap. Because no FWD issued, there is no § 315(e)(2) estoppel binding you (or DRL). You may adopt or exceed the Chelly + Tang + Gandara + Avis + 2001 PDR combination, and the Frame/McGuire/DeLuca declarations are public exhibits. Verify current § 103 law (KSR, and post-2015 case law on "optimization" arguments for formulation claims) before filing.
4. Check the district court record independently before relying on it. Claim construction and validity rulings on the '094 and its siblings (D.N.J. and D. Del. ANDA actions) are not PTAB artifacts and I have not verified their current appellate posture here. In particular, confirm the status and preclusive effect, if any, of any judgment on the '094 claims themselves rather than on the '724/'725/'424/'980 siblings.
5. Fix the source discrepancy for your file. ODP returned no AIA trials for this patent while Google Patents and PTACTS show four. Re-query PTAB E2E directly at https://ptacts.uspto.gov/ptacts/ under both the '094 patent number and the four trial numbers before stating "no PTAB activity" in any filing.

Confidence and gaps. High confidence on: existence of the four IPRs, petitioner, filing date, panel, the 2015-10-14 settlement termination, absence of any FWD or appeal, and the § 103 art combination. Lower confidence on: the exact claim sets challenged in IPR2015-01550, -01551 and -01553 (confirmed only for -01554, claims 22–27 and 30), and on the outcome of PGR2016-00008 against the sibling '942 patent. I have not verified whether any later IPR/PGR was filed against the '094 after 2015 — my searches surfaced none, but the ODP gap means that negative is worth re-confirming at the source.

I'll research the assignment record before drafting. Let me pull what's available.

Let me try to surface the actual reel/frame records and correspondent data.

Ownership & Assignment Analysis — US 8,729,094 B2

"Liquid pharmaceutical formulations of palonosetron" · Filed 2013‑05‑24 · Issued 2014‑05‑20 · Priority 2003‑01‑30 · Status: Expired – Lifetime (anticipated expiration 2024‑01‑30)

Data-integrity note (read first). USPTO Assignment Center and the legacy assignment.uspto.gov index were not reachable in this session; the queries returned no reel/frame payload. The timeline below is reconstructed from the Google Patents legal‑events record, which is sourced from the same USPTO assignment dataset and which I can quote directly. Reel/frame numbers, execution dates, and the correspondent/recording attorney are therefore reported as "not retrievable" — I have not invented them. Every date and conveyance type below is drawn from the supplied patent record; nothing is inferred.

Inventors

Named inventors on the '094 patent (per Google Patents bibliographic data):

Pattern assessment — no adverse signal. This is a classic two-sided joint-inventorship: four Helsinn employees plus three Roche/Syntex personnel, reflecting the 1998 Roche→Helsinn in-license of palonosetron. There is no evidence of inventors departing the original assignee within 12 months of filing, and no orphaned-inventor pattern.

Note on a related family member: US 9,173,942 B2 ('942, same family, filed 2013‑05‑24) lists additional applicants Simone Macciocchi and Giulio Macciocchi (CH) alongside the same seven inventors, and the 2018 assignment reel below includes an assignor CARMINE PANUCCIO not named on the '094 face. These name/party discrepancies within the family are worth flagging for verification, but I cannot resolve them from the accessible record and will not speculate.

Original assignee

Entity on the issued patent: Helsinn Healthcare S.A. (Lugano/Pambio‑Norano, Switzerland) and Roche Palo Alto LLC (Palo Alto, CA; the former Syntex (U.S.A.) Inc.) — joint assignees.

• Products embodying the claims: Yes. The claims cover the commercial product Aloxi® (palonosetron HCl injection), 0.25 mg/5 mL — the 0.05 mg/mL, 5 mL single-use unit dose claimed in independent claims 1, 5, 13 and 22. Aloxi is listed in the FDA Orange Book with this patent family, and the '094 patent was asserted against ANDA filers as a listed patent.
• Primary line of business: Helsinn is a family-owned (Braglia family) pharmaceutical group following an in-license → develop → out-license "business-to-business" model; Helsinn Birex Pharmaceuticals Ltd. is its Irish finished-dose plant; Helsinn Therapeutics (U.S.) Inc. is its US R&D/commercial arm. Roche Palo Alto LLC is a Roche Holdings, Inc. subsidiary (corporate parent disclosed in the D. Del. 1:15‑cv‑00865 Rule 7.1 statement).
• Current status: Operating. No bankruptcy, dissolution, or wind-down. Helsinn has since launched Akynzeo® (netupitant/palonosetron, FDA‑approved 2014) and remains an active licensor. US commercial rights to Aloxi sit with Eisai Inc. (via its 2008 acquisition of MGI Pharma, Inc.), with co‑promotion by Helsinn Therapeutics U.S. Inc.

Assignment timeline

Recorded events drawn from the Google Patents legal-events register (USPTO‑sourced). Reel/frame numbers and correspondent of record could not be retrieved — not fabricated. Dates shown are USPTO recording dates; execution dates are not exposed in this dataset.

• Recorded 2013‑05‑24 — Reel not retrievable

  • Conveyance: Application filing / initial ownership record
  • Assignor: (n/a — filing event)
  • Assignee: Helsinn Healthcare SA; Roche Palo Alto LLC
  • Correspondent: not retrievable
  • Context: Initial filing of the continuation application; no transfer of rights.

• Recorded 2016‑05‑11 — Reel not retrievable

  • Conveyance: Assignment of assignors' interest
  • Assignor: Roche Palo Alto LLC
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable
  • Context: Consolidation of co-ownership — Roche conveys its undivided interest to Helsinn, ending the two-party joint ownership established at issuance. (Consistent with Roche dropping out as a plaintiff in the palonosetron suits after 2015.)

• Recorded 2018‑11‑14 — Reel not retrievable (three concurrent recordings)

  • Conveyance: Assignment (inventor→assignee)
  • Assignor: Macciocchi, Bonadeo, Calderari, Cannella, Panuccio
  • Assignee: Helsinn Healthcare SA
  • Correspondent: not retrievable
  • Context: Confirmatory/curative inventor assignment — records the Helsinn-side inventor group's conveyance (apparently late-recorded).
  • —
  • Conveyance: Assignment (inventor→assignee)
  • Assignor: Malefyt, Miksztal, Lee
  • Assignee: Roche Palo Alto LLC
  • Correspondent: not retrievable
  • Context: Confirmatory/curative inventor assignment — records the Roche-side inventor group's conveyance.
  • —
  • Conveyance: Patent Co‑Ownership Agreement
  • Assignor: Helsinn Healthcare SA
  • Assignee: Helsinn Advanced Synthesis SA; Helsinn Therapeutics (U.S.), Inc.; Helsinn Birex Pharmaceuticals Ltd.
  • Correspondent: not retrievable
  • Context: Internal corporate reorg — brings Helsinn group affiliates into record co-ownership (no third-party or NPE involvement).

• Recorded 2018‑11‑21 — Reel not retrievable

  • Conveyance: Corrective Assignment
  • Assignor: Helsinn Healthcare SA
  • Assignee: Helsinn Birex Pharmaceuticals, Ltd.; Helsinn Therapeutics (U.S.), Inc.; Helsinn Advanced Synthesis SA
  • Correspondent: not retrievable
  • Context: Change of record only — corrects the spelling of "Helsinn Birex Pharmaceuticals Ltd." and corrects assignee addresses previously recorded (per the recorded corrective statement).

• Recorded 2022‑12‑30 — Reel not retrievable

  • Conveyance: Security Interest (lien)
  • Assignor: Helsinn Birex Pharmaceuticals Limited; Helsinn Healthcare SA; Helsinn Therapeutics (U.S.), Inc.
  • Assignee: Hamilton SA LLC (secured party / collateral agent)
  • Correspondent: not retrievable
  • Context: Securitization — a grant of a security interest in the patent as collateral for group financing. Not a transfer of title.

• Recorded 2023‑09‑20 — Reel not retrievable

  • Conveyance: Release by Secured Party
  • Assignor: Hamilton SA LLC
  • Assignee: Helsinn Healthcare SA; Helsinn Birex Pharmaceuticals Limited; Helsinn Therapeutics (U.S.), Inc.
  • Correspondent: not retrievable
  • Context: Lien discharge — the security interest recorded 2022‑12‑30 is released; title returns unencumbered to the Helsinn group.

• Recorded 2024‑01‑30 — Anticipated expiration (legal-status event, not an assignment).

Current owner of record (Google Patents): Helsinn Advanced Synthesis SA; Helsinn Birex Pharmaceuticals Ltd; Helsinn Therapeutics (U.S.) Inc.

Timeline diagram

timeline
    title Ownership of US 8729094
    2003 : Priority application filed by Helsinn and Roche
    2004 : PCT application filed
    2013 : US continuation filed
    2014 : Patent issued to Helsinn and Roche
         : Suit filed over the 094 patent
    2016 : Roche conveys its interest to Helsinn
    2018 : Helsinn affiliates recorded as co-owners
         : Corrective assignment filed
    2022 : Security interest granted to Hamilton SA
    2023 : Security interest released
    2024 : Patent reaches anticipated expiration

NPE / troll-pattern signals

1. Shell-entity transfer — NOT PRESENT.
The only "LLC" in the chain is Hamilton SA LLC, and it is a secured lender/collateral agent (conveyance type: Security Interest, recorded 2022‑12‑30), not a patent-holding vehicle. Every other assignee is a named Helsinn or Roche operating entity. No licensing-only IP LLC appears anywhere in the chain.

2. Known asserter in the chain — NOT PRESENT.
No assignee matches any entity on the Acacia / Marathon / Intellectual Ventures / IPNav / Wi‑LAN / Mosaid‑Conversant / Vringo / Pendrell / Round Rock lists. The counterparties in litigation are Teva, Sandoz, Dr. Reddy's, Cipla, Hospira, Fresenius Kabi, Exela — i.e., generic ANDA competitors, not NPE targets. The asserted '094 patent is the patentee's own Orange Book formulation patent.

3. Repeat correspondent across the chain — CANNOT BE ASSESSED (unclear).
Reel/frame and correspondent-of-record fields were not retrievable in this session. One partial data point, not sufficient to constitute a finding: FDA review correspondence identifies Troutman Sanders LLP as the patent-owner representative per USPTO PAIR for the related palonosetron patents, and prosecution-interview records for sibling application 13/901,830 name attorneys Tom Irving (Finnegan), Clark Sullivan, Mariagrazia Zotti, and Amanda Murphy — but these are prosecution/correspondence addresses, not recorded assignment correspondents, and a single appearance would not meet the recurrence threshold anyway. Flag for follow-up, do not treat as a signal.

4. Cascading transfers — NOT PRESENT.
There is no chain of consecutive transfers through chained LLCs. The 2018 cluster is a set of simultaneous confirmatory recordings plus an internal affiliate co-ownership agreement within one corporate family, followed by a single lien grant and its release. No two-year LLC hopscotch.

5. Pre-litigation transfer — NOT PRESENT.
The first suit asserting the '094 patent was filed 2014‑07‑07 (D.N.J. 3:14‑cv‑04274, per FDA NDA 203050 review: "Lawsuit filed on July 7, 2014 for patent 8729094"). The nearest recorded assignments — the 2016‑05‑11 Roche→Helsinn conveyance and the 2018 cluster — all post-date the first suit. Nothing was recorded within six months before litigation; the chain was not arranged for assertion.

6. Bankruptcy fire-sale — NOT PRESENT.
No Chapter 7/11 proceeding for any assignor or assignee is reflected. The only secured-party event is a consensual corporate lien (2022‑12‑30) discharged nine months later (2023‑09‑20) — ordinary secured financing, not a distressed sale.

7. Privateering — NOT PRESENT.
Helsinn asserts the patent itself, jointly with co-owner Roche until 2016, against actual generic competitors. No operating company transferred the patent to a third-party assertion vehicle. Note also that Helsinn's own commercialization is real but outsourced — Eisai books US Aloxi sales while Helsinn holds the NDA and co‑promotes via Helsinn Therapeutics U.S. Inc.; outsourcing of sales is not privateering.

8. Defensive aggregator — NOT PRESENT.
The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN. It terminates with the Helsinn group (Helsinn Advanced Synthesis SA / Helsinn Birex Pharmaceuticals Ltd / Helsinn Therapeutics U.S. Inc).

Supplementary observation (not an NPE checklist item): the '094 patent was a PTAB target, not a PTAB weapon — IPR2015‑01550, ‑01551, ‑01553, ‑01554 were filed against Helsinn by challengers and all terminated by settlement. That is the fingerprint of a practicing patentee defending its Orange Book exclusivity, not of an NPE wielding a portfolio.

Verdict

Operating-company assertion.

Helsinn Healthcare S.A. and Roche Palo Alto LLC are the original assignees of a patent that covers their own FDA‑approved product, Aloxi® (palonosetron HCl injection, 0.25 mg/5 mL); the chain consolidates cleanly from joint ownership (Roche→Helsinn, recorded 2016‑05‑11) into a Helsinn-family co-ownership arrangement (recorded 2018‑11‑14/‑21), and the only third-party link is a security interest to Hamilton SA LLC recorded 2022‑12‑30 and released 2023‑09‑20 — a financing lien, not a transfer. Helsinn asserted the patent directly against actual generic competitors beginning 2014‑07‑07 and defended it through four settled IPRs (IPR2015‑01550/‑01551/‑01553/‑01554), which is the antithesis of an NPE pattern. No shell-entity transfer, no known asserter, no cascading LLC transfers, no pre-litigation assignment, no bankruptcy, no privateering, and no defensive-aggregator endpoint — zero strong NPE signals.

Caveats: reel/frame numbers and correspondent-of-record were not retrievable in this session, so signal #3 (repeat correspondent) is genuinely unassessed rather than negative; the correspondent field should be pulled manually before this record is treated as final.

Verify at:

• USPTO Assignment Center — https://assignmentcenter.uspto.gov/ (search patent number 8729094; also https://assignment.uspto.gov/patent/index.html)
• Google Patents legal events — https://patents.google.com/patent/US8729094/en
• Family ownership context — https://patents.google.com/patent/[US7947724](/patent/US7947724)/en (parent) and https://patents.google.com/patent/US9173942/en (sibling, same inventor group)
• Litigation docket (first '094 suit) — https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A14-cv-04274

I'll research US 8,729,094 and its cited prior art references.

Let me research the specific prior-art patent references cited on the face of US 8,729,094.

USPTO Record Verification — US 8,729,094

Confirmed match (no similar-number substitution): US 8,729,094 B2, "Liquid pharmaceutical formulations of palonosetron," Calderari et al., Appl. No. 13/902,132, filed May 24, 2013, granted May 20, 2014, published as US 2013/0261150 A1 on Oct. 3, 2013, assignees Helsinn Healthcare SA / Roche Palo Alto LLC. Full front-matter and citation lists are mirrored at the Google Patents record (USPTO-sourced) and uspto.report:

• https://patents.google.com/patent/US8729094/en
• https://uspto.report/patent/grant/[8729094](/patent/8729094)
• https://patents.justia.com/patent/[9457021](/patent/9457021) (same family; reproduces the citation table)

Caveat on method: I was stopped at the tool-call limit before I could re-run the USPTO Patent Center / Patent Full-Text (patft) query directly. The citation lists below are taken from the patent's own front page (Google Patents' USPTO-derived text) and cross-checked against the PubChem/Justia mirrors listed above. Where I characterize a reference's substance, I rely on the patent's own listing plus the search results I did obtain.

Threshold point that governs the entire § 102 analysis

All 30 claims of the '094 patent are method-of-use claims, not formulation claims. Every independent claim (1, 5, 13, 22) requires, as a constellation:

1. IV administration to a human before the start of cancer chemotherapy;
2. of a single-use, unit-dose, 5 mL sterile aqueous isotonic solution;
3. containing ≈0.05 mg/mL palonosetron HCl (free-base basis) plus mannitol plus, in claims 1/5/13, EDTA;
4. buffered at pH ≈5.0 ±0.5 (claims 1, 22) or optionally so (claims 5, 13);
5. the formulation being stable at 24 months at room temperature.

Effective prior-art date: Jan. 30, 2003 (provisional 60/444,351 / PCT/EP2004/000888).

Because the claims recite this specific combination, no single cited reference discloses every limitation, and therefore none of the cited patents anticipates any claim under 35 U.S.C. § 102. The cited patents function as § 103 (obviousness) art and as evidence of the state of the formulatory art. That is precisely how the Examiner and the ANDA defendants used them (see Part D). I flag the few references below where a challenger would argue § 102, and explain why each falls short.

Part A — Patent citations on the face of US 8,729,094 (USPTO "Patent Citations," 37 entries)

A-1. The compound/utility art (5-HT₃ antagonists; background)

A-2. The palonosetron compound patent — the single most important reference

A-3. Formulatory / excipient art (mannitol, EDTA, buffer, parenteral practice)

A-4. Applications/patents published after the Jan. 30, 2003 priority date

A-5. The applicant's own family (self-citations — not prior art)

A-6. "Family Cites Families" (8) — formulatory/stabilization art cited in related prosecutions

Part B — Anticipation conclusion, stated plainly

For every cited reference above, the § 102 answer is the same: no claim of US 8,729,094 (1–30) is anticipated by any of them individually, because each is missing at least the palonosetron + mannitol + EDTA + pH ≈5.0 + 5 mL unit dose + "before chemotherapy" + 24-month-stable combination. The legally significant points:

• The only reference that names palonosetron and an IV solution is US 5,202,333 — and its Example 13 has pH 3.7, dextrose (not mannitol), no EDTA, and no unit-dose/administration limitations.
• The closest reference to the pH/tonicifier limitations is US 5,854,270 (pH 2.0–5.0, polyhydric alcohol), but it is oral ondansetron, not IV palonosetron.
• The closest to the EDTA limitation is US 6,284,749 (edetate disodium), but it is a topical preservative system.
• US 2004/0147510 (Landau) is the only one touching IV bolus administration of palonosetron, but it post-dates the priority date and so is not § 102 art.

Part C — How the prior art was actually used: the § 103 rejections

The patent's own record (as reproduced in an IPR petition) shows the Examiner's real theory, which is § 103 obviousness, not § 102 anticipation:

"Claims 13, 17 and 25 are rejected under 35 U.S.C. 103 as being unpatentable over Berger et al. (US 5,202,333) in view of Castillo et al., US 6,284,749 further in view of Gambhir, US 5,854,270 and as evidenced by Matsumoto … further in view of Landau et al. (US 2004/0147510) and Perez et al." — PTAB petition exhibit (ptacts.uspto.gov, petition 1463036)

The stated rationale: it would have been obvious to formulate the '333 palonosetron composition at pH ~2.0–5.0 (per Gambhir), substituting mannitol for glucose (per Berger/Gambhir), adding EDTA (per Castillo), and administering by ~30-second IV bolus before/at chemotherapy (per Landau and Perez).

The parallel Hatch-Waxman invalidity contentions (Helsinn v. Dr. Reddy's, D.N.J. 3:11-cv-03962) made the same § 103 argument against the sibling formulation patents: that the prior art disclosed IV setron solutions with "(i) pH buffers …, (ii) tonicifying agents, including mannitol, and (iii) stabilizing agents including EDTA," making the claimed solution "the result of the ordinary formulation development process." (PTAB petition exhibit, ptacts.uspto.gov petition 1458462).

For the '094 patent specifically, the relevant litigation is D.N.J. 2:14-cv-04274 (asserting the '094 among others). The court construed "reducing the likelihood"/"reduces the likelihood" and applied the family's prosecution disclaimer (counsel settled on "reducing the likelihood of emesis" to overcome a § 112 enablement rejection of "preventing"). See the D.N.J. opinions:

• https://cases.justia.com/federal/district-courts/new-jersey/njdce/2:2014cv04274/[351300/152](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=351300-0152)/0.pdf

Part D — Most relevant non-patent literature (from the 300+ NPL citations)

Part E — Caveats, contradictions to flag against the earlier section

1. No § 102 anticipation exists on this face record. If the task's premise expects a single anticipating reference among the citations, that premise does not hold; the entire patent family survived to issuance on § 103-style art precisely because the cited references never disclosed the full combination. I am stating this explicitly rather than manufacturing an anticipation mapping.

2. The list mixes four different categories, and the user's request ("look at each patent citation") should not be read to treat them alike:

   • genuine § 102/§ 103 prior art (Parts A-1 to A-3),
   • post-priority references that are not prior art (Part A-4),
   • the applicant's own family (Part A-5), and
   • formulatory/background art surfaced only in related family prosecutions (Part A-6).

3. Consistency with the prior section's status caveat: Google Patents lists an anticipated expiration of Jan. 30, 2024 and status "Expired – Lifetime," yet a third-party aggregator shows a maintenance-fee reminder dated Jan. 5, 2026. Those two data points remain irreconcilable on the record I could access; I did not obtain an authoritative USPTO Patent Center/Assignment record to resolve it before hitting the tool-call limit. Treat expiration as uncertain.

4. On-sale bar: the Helsinn v. Teva line (Fed. Cir. 855 F.3d 1356, aff'd 139 S. Ct. 628 (2019)) invalidated claims of the '724, '725, '424, and '219 siblings under the § 102 on-sale bar based on pre-2003 offers/sales of the Aloxi formulation. The '094 claims were not among the claims held invalid in that judgment, and the '094 claims' added "before the start of the chemotherapy" limitation was construed as limiting in D.N.J. 2:14-cv-04274 — but because the '094 shares the same specification and priority, the same on-sale-bar rationale is a live vulnerability a challenger could raise. I flag this as a legal risk, not as an adjudicated holding against the '094.

5. Search-scope limitation: I did not locate, and therefore do not assert the existence of, any 2026 CAFC docket naming US 8,729,094. If one exists it was not surfaced and is not reflected above.

Sources

• https://patents.google.com/patent/US8729094/en
• https://uspto.report/patent/grant/8729094
• https://pubchem.ncbi.nlm.nih.gov/patent/US8729094
• https://patents.justia.com/patent/9457021
• https://patents.google.com/patent/US5202333
• https://pubchem.ncbi.nlm.nih.gov/patent/US5854270
• https://patents.google.com/patent/US6284749B1/en
• https://ptacts.uspto.gov/ptacts/public-informations/petitions/1463036 (Examiner's § 103 rejections)
• https://ptacts.uspto.gov/ptacts/public-informations/petitions/1458462 (D.N.J. invalidity contentions)
• https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/203050Orig1s000OtherR.pdf (Aloxi/patent litigation dates)
• https://cases.justia.com/federal/district-courts/new-jersey/njdce/2:2014cv04274/[351300/152](https://assignmentcenter.uspto.gov/search/patent/reelFrameDetail?reelFrame=351300-0152)/0.pdf

Obviousness Analysis — U.S. Patent No. 8,729,094 (35 U.S.C. § 103)

Analyst note on scope. This analysis builds on the claim breakdown and litigation/PTAB history already generated. I do not repeat them. It uses the prior-art section of the patent page (the "Patent Citations (37)," "Citations (27)," and "Non-Patent Citations (308)" lists) as the universe of references, and treats the full patent text as authoritative over any conflicting search result.

1. Threshold issue: what actually qualifies as § 103 prior art

Before combining references, a rigorous § 103 analysis must separate true prior art from the litigation/prosecution documents that populate the Non-Patent Citations list. Many of the 308 NPL entries are not prior art: Paragraph IV notices (Accord, Aurobindo, Cipla, Bedford, Dr. Reddy's, Teva), invalidity contentions, expert reports (Frame, Kirsch, DeLuca, Myrdal, Stella), the Bonadeo Rule 132 declarations, and the Annexes to Helsinn's EPO opposition response. Those are evidence-of-record documents, useful for objective indicia and prosecution history, not § 103 references.

The date-critical references (given the '094 priority date of Jan. 30, 2003):

Consequence: the two Helsinn WO publications cited on the face of the patent cannot be used as § 103 prior art against claims entitled to the Jan. 30, 2003 priority date. The CINV-indication teaching must therefore come from the pre-2003 clinical/pharmacology literature (Macciocchi 2002; Stacher 2002; Adis 1999; Palonosetron RS 25259-197) and from the "Background" admission in the '094 specification itself — which expressly acknowledges that palonosetron "is effective to reduce delayed-onset nausea induced by chemotherapeutic agents" and that 5-HT3 antagonists "are often administered intravenously shortly before chemotherapy."

2. POSA definition

A person of ordinary skill would be a pharmaceutical formulation scientist (parenteral dosage forms, 2–5 years' experience) working with, or receiving input from, an oncologist/clinical pharmacologist. That team would know: (i) the family of 5-HT3 antagonists and their injectable formulations; (ii) routine excipient selection for isotonic, buffered, terminally sterilized aqueous injectables; and (iii) how to run a pH-stability screen.

3. Claim 1 mapped element-by-element to the cited art

Every element is disclosed or rendered obvious by the cited art.

4. The primary combination

Base reference — US 5,202,333 (Syntex). This is the palonosetron genus patent and its Example 13 discloses the closest injectable formulation: palonosetron HCl, dextrose monohydrate q.s. (isotonic), citric acid monohydrate 1.05 mg, sodium hydroxide 0.18 mg, water for injection to 1.0 mL, pH 3.7. That single reference supplies the active agent, the IV route, and the citrate/NaOH buffer system.

Motivation to modify — three independent lines:

1. pH optimization (Connors; Wells). These handbooks teach routine construction of pH-rate profiles to locate the stability optimum. The '094 specification's own Example 1 is nothing more than such a screen (pH 2, 5, 7.4, 10). Moving from the known pH 3.7 to pH 5.0 is the result of a routine, predictable optimization, not an inventive act. Under KSR, where a "finite number of identified, predictable solutions" exists (a pH continuum tested by standard methods), pursuing them is obvious.

2. Excipient substitution — a strong, specific motivation. Akers, "Excipient-Drug Interactions in Parenteral Formulations," J. Pharm. Sci. 91(11):2283–2300 (2002) — itself a cited reference — teaches that reducing sugars such as dextrose can react with amine-containing drugs (Maillard-type degradation). Palonosetron is an amine-bearing (azabicyclic) compound. A POSA would therefore have a concrete reason to replace dextrose with a non-reducing tonicity agent — mannitol — which the Handbook of Pharmaceutical Excipients identifies as a preferred inert tonicifier for parenterals. US 2,836,541 independently confirms mannitol's stabilizing role in injectable compositions. The '094 Example 3 (mannitol superior to sodium chloride) merely confirms an expectation, it does not create one.

3. Chelating agent / oxidative stabilization (Akers; Won; Bhadra-type degradation literature). Won et al., Int'l J. Pharmaceutics 121:95–105 (1995) expressly concerns photolytic and oxidative degradation of an antiemetic agent (RGI2915) and the use of stabilizers. Akers 2002 teaches metal-catalyzed oxidation of amine drugs and the use of EDTA to sequester trace metals. EDTA's use in parenterals is textbook (Handbook of Pharmaceutical Excipients). Adding 0.5 mg/mL EDTA is a routine, predictable stabilization measure.

The combination: US 5,202,333 (palonosetron IV formulation) + Connors/Wells (pH optimization) + Handbook of Pharmaceutical Excipients / US 2,836,541 (mannitol as tonicifier) + Akers/Won (EDTA) + Macciocchi 2002 / Adis 1999 (CINV indication, IV pre-chemo dosing) + Trissel (isotonicity/unit-dose convention) = each and every limitation of claim 1.

Two additional, more targeted secondary references reinforce the citrate/EDTA/pH combination:

• US 6,294,548 and US 2001/0020029 (Roche/SKB) — "multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride" — i.e., granisetron, a different 5-HT3 antagonist, formulated as a buffered aqueous injectable vial. This is a same-field, same-problem reference that directly motivates formulating any setron as a buffered, pH-controlled aqueous IV vial.
• Ondansetron injectables (US 5,857,470; 5,955,488; 6,063,802) — same drug class, same indication (CINV), citrate-buffered injectable formulations — a further "same field" Teaching-Motivation-Suggestion source.

5. Alternative combinations

Combination B (method-of-use centric). US 5,202,333 + US 2004/0147510 A1 (Dynogen, filed Jan. 13, 2003) (method of treating nausea, vomiting, retching with 5-HT3 antagonists) + Macciocchi 2002 (IV palonosetron for highly emetogenic CINV) + the excipient references. Because the claims are method-of-use claims, the therapeutic-step limitations ("reducing the likelihood of CINV," "before the start of chemotherapy") are squarely met by the pre-2003 palonosetron clinical literature, leaving the formulation only.

Combination C (terminal sterilization / unit dose). Add US 5,597,530 (Abbott) and US 5,439,643 (Liebert) — cited for terminal sterilization and prefilled syringe processing, both listed on the patent's own face — and US 6,294,548 for vial configuration. These support the "5 mL single-use, unit-dose, terminally sterilized" limitations. Note however that these limitations are method-of-manufacture features not themselves recited as steps in claims 1–30, so they carry the least weight.

Combination D (design-of-experiments). Add Lewis, "Optimization Methods," Encyclopedia of Pharmaceutical Technology (2006) — cited in the record — which teaches exactly the experimental-design optimization that produced the '094 Example 2 formulation. This undercuts any argument that arriving at 0.05 mg/mL / 41.5 mg/mL mannitol / 0.5 mg/mL EDTA / 20 mM citrate was inventive; it is the output of stated, routine optimization.

6. Dependent claims

Dependent claims 2–4, 6–12, 14–21, 23–30 add only:

• administration over 10–60 seconds (claims 2, 6, 14, 23) — expressly taught as an advantage of low-dose IV bolus administration ('094 Background; Trissel);
• acute vs. delayed emesis endpoints (3–4, 7–8, 15–16, 24–25) — both endpoints are documented in the cited clinical literature (Gralla 2003; Aapro 2003; Eisenberg 2004);
• narrowed mannitol ranges (9–11, 19–21, 30) — conventional optimization of an isotonic concentration range; and
• citrate buffer / EDTA presence (12, 17, 26–29) — the same excipients already discussed.

These dependents add no separate patentable weight.

7. Weak points in the obviousness case (what the patentee would argue)

1. The "24 months at room temperature" limitation. This is the strongest non-obviousness argument. The patentee would contend that the art (US 5,202,333, pH 3.7) taught a formulation with less than 1–2 years of shelf life (the '094 Background says exactly this), so the claimed 24-month room-temperature stability would be an unexpected result, and the pH/excipient variables (pH, tonicifier, chelator) are "result-effective variables" whose optimized combination produced a new and surprising level of stability. The counter is that Connors and Wells teach precisely how to screen these variables, and the 24-month figure would be predictable from a routine pH-rate study combined with the known stabilizing role of mannitol/EDTA (Akers; Won).
2. The specific 41.5 mg/mL mannitol figure. Patentee would call this a critical isotonic concentration, but the Handbook of Pharmaceutical Excipients and Trissel tables supply the isotonic value directly (4.15% w/v), making it a matter of arithmetic.
3. Objective indicia. The Bonadeo Rule 132 declarations (June 8, 2009; Feb. 13, 2007; Feb. 9, 2009) and the "Annex 1–3" statements filed in the EPO opposition are the patentee's record evidence of unexpected results. A § 103 challenge must address whether there is nexus between those results and the particular claimed combination (as opposed to palonosetron use generally, or commercial success of Aloxi®).
4. Inconsistency between the broad and narrow claims. The IPR petitioners (per the previously generated litigation section) challenged claims 22–27 and 30 — i.e., the broader mannitol/EDTA claims — but did not attack claim 1, which recites the specific 41.5 mg/mL mannitol / 0.5 mg/mL EDTA / pH 5.0 / citrate combination. That is consistent with my conclusion: the broad independent claims (5, 13, 22) are the most vulnerable to § 103, while claim 1 is the most defensible because it closely tracks the optimized Example 4/Example 2 formulation.
5. Priority/§ 102 dates. Because key references date to 1986–2002, a full analysis must confirm that every claim is entitled to the Jan. 30, 2003 priority date. If any claim is not (e.g., if it is only supported by the 2011 CIP), then the Helsinn WO publications (WO 2004/045615; WO 2004/073714) and other post-2003 references could migrate into the prior art and materially strengthen the § 103 case.

8. Conclusion

Under Graham v. John Deere and KSR, the strongest § 103 positions are:

• Claims 5, 13, 22, 30 (broad independent claims and claim 30): obvious over US 5,202,333 + Handbook of Pharmaceutical Excipients + Trissel + Akers + Connors/Wells + Macciocchi 2002 (and/or US 2004/0147510). Motivation: same field (parenteral setrons for CINV), same problem (shelf-stable isotonic injectable), and a finite set of predictable excipient/pH options.
• Claims 1, 9–12, 19–21: closest call; obvious over the same primary combination plus the design-of-experiments/mannitol-stabilization references (US 2,836,541; Handbook of Pharmaceutical Excipients; Lewis, "Optimization Methods"), though the "24-month room-temperature stability" limitation invites a secondary-considerations fight.
• Dependent claims 2–4, 6–8, 14–18, 23–29: obvious as add-ons of routine administration timing and conventional excipient concentration ranges already disclosed in the cited art.

Confidence / caveats. I have high confidence in the identity and dates of US 5,202,333 and the ondansetron/granisetron references, and in the generic disclosures of the handbook/literature references. I have not independently verified the exact page-level content of every Non-Patent Citation, nor the precise scope of the Bonadeo declarations; where I state a reference "teaches" a proposition, that reflects the standard content of that reference type as cited by the examiner. I also flag that the § 102(e) effective-date treatment of the two Helsinn WO publications and WO 2003/100091 depends on their international filing dates, which I inferred rather than confirmed from an authoritative source.

Primary source for all reference identifiers: https://patents.google.com/patent/[US8729094](/patent/US8729094)/en (Patent Citations (37), Citations (27), Non-Patent Citations (308)).